These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 31765385)

  • 1. Statistical determination of synergy based on Bliss definition of drugs independence.
    Demidenko E; Miller TW
    PLoS One; 2019; 14(11):e0224137. PubMed ID: 31765385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statistical assessment and visualization of synergies for large-scale sparse drug combination datasets.
    Amzallag A; Ramaswamy S; Benes CH
    BMC Bioinformatics; 2019 Feb; 20(1):83. PubMed ID: 30777010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pragmatic definition of therapeutic synergy suitable for clinically relevant in vitro multicompound analyses.
    Kashif M; Andersson C; Åberg M; Nygren P; Sjöblom T; Hammerling U; Larsson R; Gustafsson MG
    Mol Cancer Ther; 2014 Jul; 13(7):1964-76. PubMed ID: 24755197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Independent drug action and its statistical implications for development of combination therapies.
    Chen C; Liu F; Ren Y; Suttner L; Sun Z; Shentu Y; Schmidt EV
    Contemp Clin Trials; 2020 Nov; 98():106126. PubMed ID: 32853780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A New Bliss Independence Model to Analyze Drug Combination Data.
    Zhao W; Sachsenmeier K; Zhang L; Sult E; Hollingsworth RE; Yang H
    J Biomol Screen; 2014 Jun; 19(5):817-21. PubMed ID: 24492921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What is synergy? The Saariselkä agreement revisited.
    Tang J; Wennerberg K; Aittokallio T
    Front Pharmacol; 2015; 6():181. PubMed ID: 26388771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inference of synergy/antagonism between anticancer drugs from the pooled analysis of clinical trials.
    Kang W; DiPaola RS; Vazquez A
    BMC Med Res Methodol; 2013 Jun; 13():77. PubMed ID: 23758906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detecting bliss synergy in in vivo combination studies with a tumor kinetic model.
    Zhao W; Vicini P; Novick S; Anderton J; Davies G; DAngelo G; O'Day T; Yu B; Harper J; Narwal R; Roskos L; Yang H
    Pharm Stat; 2019 Nov; 18(6):688-699. PubMed ID: 31140720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction index and different methods for determining drug interaction in combination therapy.
    Lee JJ; Kong M; Ayers GD; Lotan R
    J Biopharm Stat; 2007; 17(3):461-80. PubMed ID: 17479394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bliss and Loewe interaction analyses of clinically relevant drug combinations in human colon cancer cell lines reveal complex patterns of synergy and antagonism.
    Kashif M; Andersson C; Mansoori S; Larsson R; Nygren P; Gustafsson MG
    Oncotarget; 2017 Nov; 8(61):103952-103967. PubMed ID: 29262612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Network Propagation Predicts Drug Synergy in Cancers.
    Li H; Li T; Quang D; Guan Y
    Cancer Res; 2018 Sep; 78(18):5446-5457. PubMed ID: 30054332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A generalized response surface model with varying relative potency for assessing drug interaction.
    Kong M; Lee JJ
    Biometrics; 2006 Dec; 62(4):986-95. PubMed ID: 17156272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applying synergy metrics to combination screening data: agreements, disagreements and pitfalls.
    Vlot AHC; Aniceto N; Menden MP; Ulrich-Merzenich G; Bender A
    Drug Discov Today; 2019 Dec; 24(12):2286-2298. PubMed ID: 31518641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CombiTool--a new computer program for analyzing combination experiments with biologically active agents.
    Dressler V; Müller G; Sühnel J
    Comput Biomed Res; 1999 Apr; 32(2):145-60. PubMed ID: 10337496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A formal model for analyzing drug combination effects and its application in TNF-alpha-induced NFkappaB pathway.
    Yan H; Zhang B; Li S; Zhao Q
    BMC Syst Biol; 2010 Apr; 4():50. PubMed ID: 20416113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased preclinical efficacy of irinotecan and floxuridine coencapsulated inside liposomes is associated with tumor delivery of synergistic drug ratios.
    Harasym TO; Tardi PG; Harasym NL; Harvie P; Johnstone SA; Mayer LD
    Oncol Res; 2007; 16(8):361-74. PubMed ID: 17913044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How valid are claims for synergy in published clinical studies?
    Ocana A; Amir E; Yeung C; Seruga B; Tannock IF
    Ann Oncol; 2012 Aug; 23(8):2161-2166. PubMed ID: 22314859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer.
    Nielsen LL; Lipari P; Dell J; Gurnani M; Hajian G
    Clin Cancer Res; 1998 Apr; 4(4):835-46. PubMed ID: 9563876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of drug combination effect using a Bliss independence dose-response surface model.
    Liu Q; Yin X; Languino LR; Altieri DC
    Stat Biopharm Res; 2018; 10(2):112-122. PubMed ID: 30881603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A mathematical approach to study combined effects of toxicants in vitro: evaluation of the Bliss independence criterion and the Loewe additivity model.
    Goldoni M; Johansson C
    Toxicol In Vitro; 2007 Aug; 21(5):759-69. PubMed ID: 17420112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.